论文部分内容阅读
Academia and biomedical industry are using new genomic technologies to develop biomarkers for cancer molecular classification and prediction of treatment responsiveness and clinical outcome.Such markers can be used to select patients who are most likely to benefit from a particular regimen to increase efficacy in the selected subpopulation.The identification of molecular biomarkers will enable to integrate diagnostics and therapeutics to individualize cancer therapy.